VORTIOXETINE by Cipla is understood, but is thought to be related to its enhancement of serotonergic activity in the cns through inhibition of the reuptake of serotonin (5-ht). Approved for major depressive disorder (mdd) in adults (.
Drug data last refreshed 7h ago
understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT). It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism. The contribution of these activities to…
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
Vortioxetine for Post-COVID-19 Condition
Vortioxetine to Prevent Return of Symptoms in Children With Depression
Worked on VORTIOXETINE at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.